Management of advanced colorectal cancer, part 1

American Journal of Health-System Pharmacy

Volumn 70, Issue 5, 2013, Pages 395-406

  Cersosimo, Robert J ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HAND FOOT AND MOUTH DISEASE; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84874086467     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110532     Document Type: Review

References (107)

1. Siegel R, Naishadadham D, Jemal A et al. Cancer statistics 2012. CA Cancer J Clin. 2012; 62:10-29.
2. Altekruse SF, Kosary CL, Krapcho M et al., eds., for National Cancer Institute. SEER cancer statistics review, 1975-2007. http://seer.cancer.gov/csr/ 1975-2007/(accessed 2012 Dec 4).
3. American Cancer Society. Cancer facts and figures 2012. www.cancer.org/ACS/groups/content/@epidemiologysurveilance/documents/document/ ACSPC-031941.pdf (accessed 2013 Jan 10).
4. Howlader N, Noone AM, Krapcho M et al., eds., for National Cancer Institute. SEER cancer statistics review, 1975-2008. http://seer.cancer.gov/csr/ 1975-2008/(accessed 2012 Dec 4).
5. National Cancer Institute, National Institutes of Health. Drugs approved for colon and rectal cancer. www.cancer. gov/cancertopics/druginfo/colorectal cancer (accessed 2013 Jan 28).
6. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22:1209-14.
7. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluoroura-cil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005; 23:9441-2. Letter.
8. Goldberg RM, Rothenberg ML, van Cutsem E et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007; 12:38-50.
9. Longley DB, Harkin D P, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3:330-8.
10. Hansen RM, Ryan L, Anderson T et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst. 1996; 88:668-74.
11. Weinerman B, Shah A. Fields A et al. Systemic infusion versus bolus chemotherapy in measurable colorectal cancer. Am J Clin Oncol. 1992; 15:518-23.
12. Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol. 1995; 13:1303-11.
13. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol. 1989; 7:425-32.
14. Rougier P, Pailiot B, Laplanche A et al. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Eur J Cancer. 1997; 33:1789-93.
15. Isacson S. 5-Fluorouracil and folinic acid in the treatment of colorectal carcinoma: a randomized trial of two different schedules of administration. Second International Conference on Gastro-Intestinal Cancer, Jerusalem, Israel; 1989 Aug 27-Sep 1.
16. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16:301-8.
17. Buroker TR, O'Connell MJ, Wieand HS et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol. 1994; 12:14-20.
18. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004; 22:3766-75.
19. De Gramont A, Krulik M, Cady J et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol. 1988; 24:1499-503.
20. De Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leu-covorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997; 15:808-15.
21. National Comprehensive Cancer Network. Practice guidelines in oncology 2012, version colon cancer. www.nccn. org/professionals/physician-gls/pdf/colon. pdf (accessed 2012 Dec 4).
22. Fusilev (levoleucovorin) prescribing information. Irvine, CA: Spectrum Pharmaceuticals; 2011 May.
23. Kovoor PA, Karim SM, Marshall JL. Is levoleucovorin an alternative to racemic leucovorin? A literature review. Clin Colorectal Cancer. 2009; 8:200-6.
24. Camptosar (irinotecan) prescribing information. New York, NY: Pharmacia & Upjohn Co, Division of Pfizer Inc.; 2010 Aug.
25. Saltz LB, Cox JV, Blanke C et al., for the Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for meta-static colorectal cancer. N Engl J Med. 2000; 343:905-14.
26. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluoro-uracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355:1041-7.
27. Kohne CH, van Cutsem E, Wils JA et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organization for Research and Treatment of Cancer Gastrointestinal Group study 40986. J Clin Oncol. 2005; 23:4811-4.
28. Mitry E, Tournigand C, Andre T et al. Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer: a pooled analysis of 254 patients included in 2 randomised trials. ASCO annual meeting proceedings (post-meeting edition). J Clin Oncol. 2004; 22(suppl):abstract 3576.
29. Souglakos J, Androulakis N, Syrigos K et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006; 94:798-805.
30. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007; 25:1670-6.
31. Masi G, Vasile E, Loupakis F et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011; 103:21-30.
32. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22:229-37.
33. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX 4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005; 23:4866-75.
34. Xeloda (capecitabine) prescribing information. South San Francisco, CA: Genentech; 2011 Feb.
35. Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000; 18:1337-45.
36. Feliu J, Escudero P, Llosa F et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J Clin Oncol. 2005; 23:3104-11.
37. Hyodo I, Shirao K, Doi T et al. A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2006; 36:410-7.
38. Lee JJ, Kim TM, Yu SJ et al. Single-agent capecitabine in patients with meta-static colorectal cancer refractory to 5-fluorouracil-leucovorin chemotherapy. Jpn J Clin Oncol. 2004; 34:400-4.
39. Hoff PM, Pazdur R, Lassere Y et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol. 2004; 22:2078-83.
40. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intra-venous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001; 19:2282-92.
41. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001; 19:4097-106.
42. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer. 2004; 90:1190-7.
43. Twelves C, for the Xeloda colorectal cancer group. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large phase III trials. Eur J Cancer. 2002; 38(suppl 2):15-20.
44. Haller DG, Cassidy J, Clarke SJ et al. Potential regional differences for the tol-erability profiles of fluoropyrimidines. J Clin Oncol. 2008; 26:2118-23.
45. Midgley R, Kerr DJ. Capecitabine: have we got the dose right? Nat Clin Pract Oncol. 2009; 6:17-24.
46. Park SH, Bang SM, Cho EK et al. Firstline chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology. 2004; 66:353-7.
47. Munoz A, Salud A, Alonso V et al. Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC). J Clin Oncol. 2004; 22(suppl):272S, abstract 3610.
48. Patt YZ, Lee FC, Liebmann JE et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-time chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol. 2007; 30:350-7.
49. Gannatas C, Michalaki V, Gennatas S et al. Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer. Anticancer Res. 2008; 28:1923-6.
50. Garcia-Alfonso P, Munoz-Martin A, Mendez-Urena M et al. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer. 2009; 101:1039-43.
51. Cartwright T, Lopez T, Vukelja SJ et al. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer. 2005; 5:50-6.
52. Rea DW, Nortier JW, Ten Bokkel Huinink WW et al. A phase I/II pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol. 2005; 16:1123-32.
53. Kim TW, Kang WK, Chang HM et al. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial. Acta Oncol. 2005; 44:230-5.
54. Barrios CH, Viola F, Camill-Coura L et al. Phase II study of capecitabine and irinotecan as first-line treatment in metastatic colorectal cancer: first trial of the Brazilian Oncology Consortium (BOC-CRC). J Clin Oncol. 2004; 22(suppl):abstract 300S.
55. El-Rayes BF, Zalupski MM, Manza SG et al. Phase-II study of dose-attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemother Pharmacol. 2008; 61:283-9.
56. Ahn J, Jung KH, Park YS et al. Phase II trial of irinotecan and capecitabine in patients with advanced colorectal cancer (ACRC). J Clin Oncol. 2005; 23(suppl):abstract 3714.
57. Zidan J, Basher W, Chetver L et al. Firstline treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma. J Clin Gastroenterol. 2012; 46:e27-30.
58. Bajetta E, di Bartolomeo M, Mariani L et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer. 2004; 100:279-87.
59. Borner MM, Bernhard J, Dietrich D et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol. 2005; 16:282-8.
60. Montagnani F, Chiriatti A, Licitra S et al. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2010; 9:243-7.
61. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007; 25:4779-86.
62. Eloxatin (oxaliplatin) prescribing information. New York, NY: sanofi-aventis; 2009.
63. Reddy GK, Gibson AD, Price N. Evolution of FOLFOX regimens in the treatment of advanced colorectal cancer. Clin Colorect Cancer. 2005; 4:296-9.
64. de Gramont A, Gastiaburu J, Tournigand C et al. Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 hours infusion in pretreated metastatic colorectal cancer. ASCO Ann Meeting Proc. 1994; 13:220, abstract 666.
65. de Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated meta-static colorectal cancer. Eur J Cancer. 1997; 33:214-9.
66. Andre T, Louvet C, Raymond E et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX 3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol. 1998; 9:1251-3.
67. Andre T, Bensmaine MA, Louvet C et al. Multicenter phase II trial of bi-monthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol. 1999; 17:3560-8.
68. Goldberg RM, Sargent DJ, Morton R et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer; a North American Intergroup trial. J Clin Oncol. 2006; 24:3347-53.
69. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18:2938-47.
70. Kim JH, Oh DY, Kim YJ et al. Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. J Korean Med Sci. 2005; 20:806-10.
71. Libutti SK, Saltz LB, Tepper JE. Colon cancer. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:1268.
72. Shimizu T, Satoh T, Tamura K et al. Oxaliplatin/fluorouracil-leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. Int J Clin Oncol. 2007; 12:218-23.
73. Goldstein D, Mitchell P, Michael M et al. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer. 2005; 92:832-7.
74. Matsumoto S, Nishimura T, Kanai M et al. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study. Chemotherapy. 2008; 54:395-403.
75. Maindrault-Goebel F, de Gramont A, Louvet C et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer. 2001; 37:1000-5.
76. Maindrault-Goebel F, de Gramont A, Louvet C et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48 hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol. 2000; 11:1477-83.
77. de Gramont A, Buyse M, Abrahantes JC et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol. 2007; 25:3224-9.
78. Tournigand C, Cervantes A, Andre T et al. OPTIMOX 1: a randomized study of FOLFOX 4 or FOLFOX 7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol. 2006; 24:394-400.
79. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol. 2009; 27:5727-33.
80. Zhuang L, Bai J, Huang H et al. Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimens for untreated metastatic advanced colorectal cancer. Oncol Res. 2010; 18:437-44.
81. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22:2084-91.
82. Feliu J, Salud A, Escudero P et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years with advanced/metastatic colorectal cancer. Br J Cancer. 2006; 94:969-75.
83. Makatsoris T, Kalofonos H P, Aravantinos G et al. A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. Int J Gastrointest Cancer. 2005; 35:103-9.
84. Karacetin D, Yalcin B, Okten B et al. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer. J BUON. 2009; 14:605-8.
85. Li YH, Luo HY, Wang FH et al. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2010; 136:503-10.
86. Comella P, Natale D, Farris A et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Final results of the Southern Italy Cooperative Oncology Group trial 0108. Cancer. 2005; 104:282-9.
87. Yaman E, Uner A, Er O et al. Capecitabine plus oxaliplatin (Xelox) in the treatment of chemotherapy-naïve patients with metastatic colorectal cancer. Med Oncol. 2007; 24:431-5.
88. Borner MM, Dietrich D, Stupp R et al. Phase II study of capecitabine and oxaliplatin in first-line and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002; 20:1759-66.
89. Zeuli M, Nartdoni C, Pino MS et al. Phase II study of capecitabine and oxali-platin as first-line treatment in advanced colorectal cancer. Ann Oncol. 2003; 14:1378-82.
90. Shields AF, Zalupski MM, Marshall JL et al. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer. 2004; 100:531-7.
91. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2003; 21:1307-12.
92. Moreno-Solorzano I, Ibeas-Rollan R, Monzo-Planella M et al. Two doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer. Clin Colorectal Cancer. 2007; 6:634-40.
93. Sakar B, Gumus M, Basaran M et al. XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer. Oncology. 2007; 73:298-304.
94. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008; 26:3523-9.
95. Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008; 26:2006-12.
96. Porschen R, Arkenau HT, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in meta-static colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007; 25:4217-23.
97. Diaz-Rubio E, Tabernero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin compared with continuous infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol. 2007; 25:4224-30.
98. Ducreux M, Bennouna J, Hebbar M et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil-leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer. 2011; 128:682-90.
99. Martoni AA, Pinto C, DiFabio F et al. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomized study (FOCA trial). Eur J Cancer. 2006; 42:3161-8.
100. Pfeiffer P, Serbye H, Ehrsson H et al. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX) in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Ann Oncol. 2006; 17:252-8.
101. Kakolyris S, Souglakos J, Polyzos A et al. Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. Oncology. 2008; 74:31-6.
102. Heras P, Kritikos K, Hatzopoulos A et al. Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer. Am J Ther. 2009; 16:319-22.
103. Rothenberg ML, Cox JV, Butts C et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III non-inferiority study. Ann Oncol. 2008; 19:1720-6.
104. Arkenau HT, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil-leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol. 2008; 26:5910-7.
105. Zhao G, Gao P, Yang KH et al. Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis. Colorectal Dis. 2010; 12:615-23.
106. Zhang C, Wang J, Gu H et al. Capecitabine plus oxalaplatin compared with 5-fluorouracil plus oxalaplatin in meta-static colorectal cancer: meta-analysis of randomized controlled trials. Oncol Lett. 2012; 3:831-8.
107. Masi G, Allegrini G, Cupini S et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil-leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol. 2004; 15:1766-72.